vascular endothelial growth factors

Summary

Summary: A family of angiogenic proteins that are closely-related to VASCULAR ENDOTHELIAL GROWTH FACTOR A. They play an important role in the growth and differentiation of vascular as well as lymphatic endothelial cells.

Top Publications

  1. ncbi Angiogenesis in cancer and other diseases
    P Carmeliet
    The Center for Transgene Technology and Gene Therapy, Flanders Interuniversity Institute for Biotechnology, KU Leuven, Belgium
    Nature 407:249-57. 2000
  2. ncbi Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele
    P Carmeliet
    Center for Transgene Technology and Gene Therapy, Flanders Interuniversity Institute for Biotechnology, Leuven, Belgium
    Nature 380:435-9. 1996
  3. ncbi Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene
    N Ferrara
    Department of Cardiovascular Research, Genentech Inc, South San Francisco, California 94080, USA
    Nature 380:439-42. 1996
  4. ncbi Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3'-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation
    H P Gerber
    Department of Cardiovascular Research, Genentech, Inc, South San Francisco, California 94080, USA
    J Biol Chem 273:30336-43. 1998
  5. ncbi Hypoxia--a key regulatory factor in tumour growth
    Adrian L Harris
    Molecular Oncology Laboratories, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford, UK
    Nat Rev Cancer 2:38-47. 2002
  6. ncbi How do angiopoietins Tie in with vascular endothelial growth factors?
    Pipsa Saharinen
    Molecular and Cancer Biology Program, Biomedicum Helsinki, University of Helsinki, Finland
    Curr Opin Hematol 17:198-205. 2010
  7. ncbi Vascular endothelial growth factors and receptors: anti-angiogenic therapy in the treatment of cancer
    Sònia Tugues
    Uppsala University, Dept of Immunology, Genetics and Pathology, Rudbeck Laboratory, Dag Hammarskjoldsv 20, 751 85 Uppsala, Sweden
    Mol Aspects Med 32:88-111. 2011
  8. ncbi The biology of VEGF and its receptors
    Napoleone Ferrara
    Department of Molecular Oncology, Genentech, Inc, 1 DNA Way, South San Francisco, California 94080, USA
    Nat Med 9:669-76. 2003
  9. ncbi Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF
    J Holash
    Regeneron Pharmaceuticals, 777 Old Saw Mill River Road, Tarrytown, NY 10591, USA
    Science 284:1994-8. 1999
  10. ncbi ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration
    Stephen R Wedge
    Department of Cancer and Infection Research, AstraZeneca, Cheshire SK10 4TG, United Kingdom
    Cancer Res 62:4645-55. 2002

Research Grants

  1. Role of a9b1 Integrin in lymphangiogenesis
    Nicholas Vlahakis; Fiscal Year: 2007
  2. VEGFs in Artery-Vein Imbalance in AIDS-Kaposi Sarcoma
    Parkash Gill; Fiscal Year: 2009
  3. VEGFs in Artery-Vein Imbalance in AIDS-Kaposi Sarcoma
    Parkash Gill; Fiscal Year: 2007
  4. Vascular endothelial growth factor induced lung edema
    Robert Kaner; Fiscal Year: 2004
  5. A Novel Model to Study Retinopathy of Prematurity
    David Moscatelli; Fiscal Year: 2003
  6. Augmentation of Lymphangiogenesis by Increased Fluid Channeling in Mouse Skin
    Jeremy Goldman; Fiscal Year: 2007
  7. VEGFs in tumor lymphatic metastasis
    HAROLD FISHER DVORAK; Fiscal Year: 2010
  8. THE MAJOR ANGIOGENIC FACTORS IN PLACENTAL ANGIOGENESIS
    Lawrence Reynolds; Fiscal Year: 2004
  9. Integrins and bone matrix in prostate cancer
    Tatiana Byzova; Fiscal Year: 2006
  10. Integrins and bone matrix in prostate cancer
    Tatiana Byzova; Fiscal Year: 2003

Detail Information

Publications221 found, 100 shown here

  1. ncbi Angiogenesis in cancer and other diseases
    P Carmeliet
    The Center for Transgene Technology and Gene Therapy, Flanders Interuniversity Institute for Biotechnology, KU Leuven, Belgium
    Nature 407:249-57. 2000
    ..This integrated understanding is leading to the development of a number of exciting and bold approaches to treat cancer and other diseases. But owing to several unanswered questions, caution is needed...
  2. ncbi Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele
    P Carmeliet
    Center for Transgene Technology and Gene Therapy, Flanders Interuniversity Institute for Biotechnology, Leuven, Belgium
    Nature 380:435-9. 1996
    ....
  3. ncbi Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene
    N Ferrara
    Department of Cardiovascular Research, Genentech Inc, South San Francisco, California 94080, USA
    Nature 380:439-42. 1996
    ..Angiogenesis and blood-island formation were impaired, resulting in several developmental anomalies. Furthermore, VEGF-null embryonic stem cells exhibit a dramatically reduced ability to form tumours in nude mice...
  4. ncbi Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3'-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation
    H P Gerber
    Department of Cardiovascular Research, Genentech, Inc, South San Francisco, California 94080, USA
    J Biol Chem 273:30336-43. 1998
    ..Inhibition of apoptosis may represent a major aspect of the regulatory activity of VEGF on the vascular endothelium...
  5. ncbi Hypoxia--a key regulatory factor in tumour growth
    Adrian L Harris
    Molecular Oncology Laboratories, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford, UK
    Nat Rev Cancer 2:38-47. 2002
    ..Many elements of the hypoxia-response pathway are therefore good candidates for therapeutic targeting...
  6. ncbi How do angiopoietins Tie in with vascular endothelial growth factors?
    Pipsa Saharinen
    Molecular and Cancer Biology Program, Biomedicum Helsinki, University of Helsinki, Finland
    Curr Opin Hematol 17:198-205. 2010
    ....
  7. ncbi Vascular endothelial growth factors and receptors: anti-angiogenic therapy in the treatment of cancer
    Sònia Tugues
    Uppsala University, Dept of Immunology, Genetics and Pathology, Rudbeck Laboratory, Dag Hammarskjoldsv 20, 751 85 Uppsala, Sweden
    Mol Aspects Med 32:88-111. 2011
    b>Vascular endothelial growth factors (VEGFs) are critical regulators of vascular and lymphatic function during development, in health and in disease. There are five mammalian VEGF ligands and three VEGF receptor tyrosine kinases...
  8. ncbi The biology of VEGF and its receptors
    Napoleone Ferrara
    Department of Molecular Oncology, Genentech, Inc, 1 DNA Way, South San Francisco, California 94080, USA
    Nat Med 9:669-76. 2003
    ..VEGF inhibition is also being tested as a strategy for the prevention of angiogenesis, vascular leakage and visual loss in age-related macular degeneration...
  9. ncbi Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF
    J Holash
    Regeneron Pharmaceuticals, 777 Old Saw Mill River Road, Tarrytown, NY 10591, USA
    Science 284:1994-8. 1999
    ....
  10. ncbi ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration
    Stephen R Wedge
    Department of Cancer and Infection Research, AstraZeneca, Cheshire SK10 4TG, United Kingdom
    Cancer Res 62:4645-55. 2002
    ..4 cm(3) volume. ZD6474 is currently in Phase I clinical development as a once-daily oral therapy in patients with advanced cancer...
  11. ncbi Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics
    H Zhong
    The Johns Hopkins Oncology Center, Brady Urological Institute, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, USA
    Cancer Res 60:1541-5. 2000
    ..These data indicate that pharmacological agents that target PI3K, AKT, or FRAP in tumor cells inhibit HIF-1alpha expression and that such inhibition may contribute to therapeutic efficacy...
  12. ncbi Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter causes motor neuron degeneration
    B Oosthuyse
    The Center for Transgene Technology and Gene Therapy, Flanders Interuniversity Institute for Biotechnology, KU Leuven, Leuven, B 3000, Belgium
    Nat Genet 28:131-8. 2001
    ..Acute ischemia is known to cause nonselective neuronal death. Our results indicate that chronic vascular insufficiency and, possibly, insufficient Vegf-dependent neuroprotection lead to the select degeneration of motor neurons...
  13. ncbi Vascular endothelial growth factor is a secreted angiogenic mitogen
    D W Leung
    Department of Molecular Biology, Genetech, South San Francisco, CA 94080
    Science 246:1306-9. 1989
    ..Human 293 cells transfected with an expression vector containing a bovine or human VEGF cDNA insert secrete an endothelial cell mitogen that behaves like native VEGF...
  14. ncbi Molecular and biological properties of vascular endothelial growth factor
    N Ferrara
    Department of Cardiovascular Research, Genentech Inc, South San Francisco, CA 94080, USA
    J Mol Med (Berl) 77:527-43. 1999
    ..Currently, both therapeutic angiogenesis using recombinant VEGF or VEGF gene transfer and inhibition of VEGF-mediated pathological angiogenesis are being pursued...
  15. ncbi Neuropilin-1 conveys semaphorin and VEGF signaling during neural and cardiovascular development
    Chenghua Gu
    Department of Neuroscience, The Johns Hopkins University School of Medicine, 725 North Wolfe Street, Baltimore, MD 21205, USA
    Dev Cell 5:45-57. 2003
    ..multiple ligands from structurally distinct families, including secreted semaphorins (Sema) and vascular endothelial growth factors (VEGF)...
  16. ncbi Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1
    J A Forsythe
    Department of Physiology, University of Maryland School of Medicine, Baltimore, 21201, USA
    Mol Cell Biol 16:4604-13. 1996
    ..VEGF mRNA was not induced by hypoxia in mutant cells that do not express the HIF-1beta (ARNT) subunit. These findings implicate HIF-1 in the activation of VEGF transcription in hypoxic cells...
  17. ncbi Impaired myocardial angiogenesis and ischemic cardiomyopathy in mice lacking the vascular endothelial growth factor isoforms VEGF164 and VEGF188
    P Carmeliet
    The Center for Transgene Technology and Gene Therapy, Flanders Interuniversity Institute for Biotechnology, KU Leuven, Belgium
    Nat Med 5:495-502. 1999
  18. ncbi The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA
    K A Houck
    Department of Molecular Biology, Genetech, Inc, South San Francisco, California 94080
    Mol Endocrinol 5:1806-14. 1991
    ..Thus, alternative splicing of VEGF RNA can produce four polypeptides with strikingly different secretion patterns, which suggests multiple physiological roles for this family of proteins...
  19. ncbi Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis
    G Bergers
    Department of Biochemistry and Biophysics, University of California, 513 Parnassus Avenue, San Francisco, California 94143, USA
    Nat Cell Biol 2:737-44. 2000
    ..Absence of MMP-2 does not impair induction of angiogenesis, but retards tumour growth, whereas lack of urokinase has no effect. Our results show that MMP-9 is a component of the angiogenic switch...
  20. ncbi Vascular endothelial growth factor expression of intercellular adhesion molecule 1 (ICAM-1), vascular cell adhesion molecule 1 (VCAM-1), and E-selectin through nuclear factor-kappa B activation in endothelial cells
    I Kim
    National Creative Research Initiatives Center for Cardiac Regeneration, and the Department of Urology, Chonbuk National University School of Medicine, Chonju, 560-180, Republic of Korea
    J Biol Chem 276:7614-20. 2001
    ..The existence of parallel inverse signaling implies that the induction of adhesion molecule expression by VEGF is very finely regulated...
  21. ncbi Vascular endothelial growth factor and vascular targeting of solid tumors
    R A Brekken
    The Hope Heart Institute, Department of Vascular Biology, Seattle, WA 98104 2046, USA
    Anticancer Res 21:4221-9. 2001
    ..We conclude that 2C3 might have dual activity as an anti-angiogenic agent by inhibiting VEGFR2 activity and as a vascular targeting agent for selective drug delivery to tumor vessels...
  22. ncbi Development of endothelial cell lines from embryonic stem cells: A tool for studying genetically manipulated endothelial cells in vitro
    G Balconi
    Istituto di Ricerche Farmacologiche Mario Negri G B, R S, E D, Milan, Italy
    Arterioscler Thromb Vasc Biol 20:1443-51. 2000
    ..We propose that this approach may be useful for obtaining endothelial cells carrying gene mutations that are lethal at very early stages of development...
  23. ncbi VEGF165 mediates formation of complexes containing VEGFR-2 and neuropilin-1 that enhance VEGF165-receptor binding
    Shay Soker
    Department of Urology, Children s Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA
    J Cell Biochem 85:357-68. 2002
    ..These complexes are formed on the surface of EC and in a juxtacrine manner via association of tumor cell NRP1 and EC KDR...
  24. ncbi Intensity of vascular endothelial growth factor expression is associated with increased risk of recurrence and decreased disease-free survival in papillary thyroid cancer
    C M Lennard
    Departments of Otolaryngology, Clinical Investigation and Pediatrics, Walter Reed Army Medical Center, Washington, DC, USA
    Surgery 129:552-8. 2001
    ..007). CONCLUSIONS: These data demonstrate that the immunohistochemical pattern of VEGF staining in the initial surgical specimen is strongly associated with the incidence of local and distant metastasis in papillary thyroid cancer...
  25. ncbi VEGF-Trap: a VEGF blocker with potent antitumor effects
    Jocelyn Holash
    Regeneron Pharmaceuticals, Incorporated, 777 Old Saw Mill River Road, Tarrytown, NY 10591, USA
    Proc Natl Acad Sci U S A 99:11393-8. 2002
    ..VEGF-Trap-mediated blockade may be superior to that achieved by other agents, such as monoclonal antibodies targeted against the VEGF receptor...
  26. ncbi The role of endotoxin/lipopolysaccharide in surgically induced tumour growth in a murine model of metastatic disease
    G P Pidgeon
    Royal College of Surgeons in Ireland, Department of Surgery, Beaumont Hospital, Dublin, Ireland
    Br J Cancer 81:1311-7. 1999
    ..These data indicate that endotoxin introduced during surgery is associated with the enhanced growth of metastases following surgical trauma, by altering the critical balances governing cellular growth and angiogenesis...
  27. ncbi Vascular endothelial growth factors: biology and current status of clinical applications in cardiovascular medicine
    Seppo Yla-Herttuala
    Department of Biotechnology and Molecular Medicine, A I Virtanen Institute, Kuopio University, Kuopio, Finland
    J Am Coll Cardiol 49:1015-26. 2007
    ..Here, we review the biology and effects of VEGFs as well as the current status of clinical applications and future perspectives of the therapeutic use of VEGFs in cardiovascular medicine...
  28. ncbi Contact inhibition of VEGF-induced proliferation requires vascular endothelial cadherin, beta-catenin, and the phosphatase DEP-1/CD148
    Maria Grazia Lampugnani
    FIRC Institute of Molecular Oncology, 20139 Milan, Italy
    J Cell Biol 161:793-804. 2003
    ..In sparse cells or in VE-cadherin-null cells, this phenomenon cannot occur and the receptor is fully activated by the growth factor...
  29. ncbi Release of the angiogenic cytokine vascular endothelial growth factor (VEGF) from platelets: significance for VEGF measurements and cancer biology
    R E Banks
    ICRF Cancer Medicine Research Unit, St James s University Hospital, Leeds UK
    Br J Cancer 77:956-64. 1998
    ..e.g. wound healing, and in tumour metastasis, when platelets adhering to circulating tumour cells may release VEGF at points of adhesion to endothelium, leading to hyperpermeability and extravasation of cells...
  30. ncbi Hypoxia-inducible factor-1alpha is a positive factor in solid tumor growth
    H E Ryan
    Department of Biology, University of California, San Diego 92093 0366, USA
    Cancer Res 60:4010-5. 2000
    ..The evidence from these experiments indicates that hypoxic response via HIF-1alpha is an important positive factor in solid tumor growth and that HIF-1alpha affects tumor expansion in ways unrelated to its regulation of VEGF expression...
  31. ncbi Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis
    C Suri
    Regeneron Pharmaceuticals, Inc, Tarrytown, New York 10591, USA
    Cell 87:1171-80. 1996
    ..Angiopoietin-1 seems to play a crucial role in mediating reciprocal interactions between the endothelium and surrounding matrix and mesenchyme...
  32. ncbi Vascular endothelial growth factor expression in untreated osteosarcoma is predictive of pulmonary metastasis and poor prognosis
    M Kaya
    Department of Orthopedic Surgery, Sapporo Medical University School of Medicine, Hokkaido, Japan
    Clin Cancer Res 6:572-7. 2000
    ....
  33. ncbi Increased vascular endothelial growth factor expression but impaired vascular endothelial growth factor receptor signaling in the myocardium of type 2 diabetic patients with chronic coronary heart disease
    Ferdinando Carlo Sasso
    Department of Geriatrics and Metabolic Disease, Second University of Naples, Naples, Italy
    J Am Coll Cardiol 46:827-34. 2005
    ..The aim of the present study was to evaluate the expression and the activity of vascular endothelial growth factor (VEGF) in the hearts of diabetic patients with chronic coronary heart disease (CHD)...
  34. ncbi The carboxyl-terminal domain (111-165) of vascular endothelial growth factor is critical for its mitogenic potency
    B A Keyt
    Department of Cardiovascular Research, Genentech, Inc, South San Francisco, California 94080, USA
    J Biol Chem 271:7788-95. 1996
    ..The present findings indicate that removal of the carboxyl-terminal domain, whether it is due to alternative splicing of mRNA or to proteolysis, is associated with a significant loss in bioactivity...
  35. ncbi Vascular endothelial growth factors and angiogenesis in eye disease
    A N Witmer
    Ocular Angiogenesis Group, Department of Ophthalmology, University of Amsterdam, Amsterdam, The Netherlands
    Prog Retin Eye Res 22:1-29. 2003
    ..On the other hand, this paracrine relation and other physiological functions of VEGFs may be endangered by therapeutic VEGF inhibition, as is currently used in several clinical trials in DR and AMD...
  36. ncbi Vascular endothelial growth factor (VEGF) upregulates BCL-2 and inhibits apoptosis in human and murine mammary adenocarcinoma cells
    G P Pidgeon
    Department of Surgery, Royal College of Surgeons in Ireland, Beaumont Hospital, Beaumont, Dublin 9, Ireland
    Br J Cancer 85:273-8. 2001
    ..Therefore, in addition to its role in angiogenesis and vessel permeability, VEGF acts as a survival factor for tumour cells, inducing Bcl-2 expression and inhibiting tumour cell apoptosis...
  37. ncbi Blood vessels and nerves: common signals, pathways and diseases
    Peter Carmeliet
    Center for Transgene Technology and Gene Therapy, Flanders Interuniversity Institute for Biotechnology, Katholieke Universiteit Leuven, Campus Gasthuisberg, Herestraat 49, B 3000, Leuven, Belgium
    Nat Rev Genet 4:710-20. 2003
    ..The realization that both systems use common genetic pathways should not only form links between vascular biology and neuroscience, but also promises to accelerate the discovery of new mechanistic insights and therapeutic opportunities...
  38. ncbi VEGF receptor signalling - in control of vascular function
    Anna Karin Olsson
    Department of Genetics and Pathology, Rudbeck Laboratory, Dag Hammarskjöldv 20, 751 85 Uppsala, Sweden
    Nat Rev Mol Cell Biol 7:359-71. 2006
    ..Recent insights have shed light onto VEGFR signal transduction and the interplay between different VEGFRs and VEGF co-receptors in development, adult physiology and disease...
  39. ncbi Expression of vascular endothelial growth factor as a prognostic factor in node-positive squamous cell carcinoma in the thoracic esophagus: long-term follow-up study
    Yutaka Ogata
    Department of Surgery, Kurume University School of Medicine, 67 Asahi Machi, Kurume, Fukuoka 830 0011, Japan
    World J Surg 27:584-9. 2003
    ..Accordingly, VEGF expression in the tumor cells could be a useful prognostic factor for esophageal cancer, particularly in node-positive patients...
  40. ncbi Connective tissue growth factor as a major angiogenic agent that is induced by hypoxia in a human breast cancer cell line
    T Shimo
    Department of Biochemistry and Molecular Dentistry, Okayama University Graduate School of Medicine and Dentistry, 2-5-1 Shikata-cho, 700-8525, Okayama, Japan
    Cancer Lett 174:57-64. 2001
    ..This is the first evidence that human cancer cells differentially express CTGF protein and mRNA under the control of hypoxic conditions...
  41. ncbi Clinical implications of circulating angiogenic factors in cancer patients
    R T Poon
    Department of Surgery, The University of Hong Kong Medical Center, Queen Mary Hospital, Hong Kong, China
    J Clin Oncol 19:1207-25. 2001
    ..Angiogenesis, a process fundamental to tumor growth, is regulated by angiogenic factors. This article reviews prognostic and other clinical implications of circulating angiogenic factors in cancer patients...
  42. ncbi Interleukin 8 and vascular endothelial growth factor -- prognostic factors in human gastric carcinomas?
    S Kido
    First Department of Internal Medicine, Hiroshima University School of Medicine, Hiroshima, Japan
    Eur J Cancer 37:1482-7. 2001
    ..05) than those of patients with tumours displaying low IL-8 and VEGF expression. The results suggest that IL-8 and VEGF may be independent and important prognostic factors in human gastric carcinomas...
  43. ncbi VEGF signaling through neuropilin 1 guides commissural axon crossing at the optic chiasm
    Lynda Erskine
    School of Medical Sciences, Institute of Medical Sciences, University of Aberdeen, Aberdeen, AB25 2ZD, UK
    Neuron 70:951-65. 2011
    ..These findings have identified a permissive midline signal for axons at the chiasm midline and provide in vivo evidence that VEGF-A is an essential axon guidance cue...
  44. ncbi The regulation of vascular endothelial growth factors (VEGF-A, -C, and -D) expression in the retinal pigment epithelium
    Yasuhiro Ikeda
    Department of Ophthalmology, Graduate School of Medical Sciences, Kyushu University, 3 1 1 Maidashi, Higashi ku, Fukuoka 812 8582, Japan
    Exp Eye Res 83:1031-40. 2006
    ..These findings suggest the possibility that VEGF-C and VEGF-D expression in RPE modify the ocular angiogenesis as angiogenic stimulators...
  45. ncbi Vascularization of the mouse embryo: a study of flk-1, tek, tie, and vascular endothelial growth factor expression during development
    D J Dumont
    Division of Molecular and Developmental Biology, Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada
    Dev Dyn 203:80-92. 1995
    ..These results suggest a possible dual role for VEGF which includes a chemotactic and/or a cellular maintenance role for VEGF during vascularization of the mouse embryo...
  46. ncbi Impaired angiogenesis in the remnant kidney model: I. Potential role of vascular endothelial growth factor and thrombospondin-1
    D H Kang
    Division of Nephrology, University of Washington, Seattle, WA, USA
    J Am Soc Nephrol 12:1434-47. 2001
    ..The impaired angiogenesis may be mediated by alterations in the renal expression of TSP-1 and VEGF, with the latter being regulated by macrophage-associated cytokines...
  47. ncbi Walking the walk: migration and other common themes in blood and vascular development
    David Traver
    Children s Hospital, Howard Hughes Medical Institute, Harvard University Medical School, Boston, MA 02115, USA
    Cell 108:731-4. 2002
    ..Their work suggests that an ancestral function of VEGF was to guide blood cell migration and highlights the conservation of at least one aspect of VEGF signaling during evolution...
  48. ncbi Vascular endothelial growth factor receptor-2 and neuropilin-1 form a receptor complex that is responsible for the differential signaling potency of VEGF(165) and VEGF(121)
    G B Whitaker
    Department of Cardiovascular Research, Procter and Gamble Pharmaceuticals, Health Care Research Center, 8700 Mason Montgomery Road, Mason, Ohio 45040, USA
    J Biol Chem 276:25520-31. 2001
    ..Taken together, these data suggest a receptor-clustering role for Npn-1, as opposed to Npn-1 behaving as an affinity-converting subunit...
  49. ncbi Neuropilin-2 is a receptor for the vascular endothelial growth factor (VEGF) forms VEGF-145 and VEGF-165 [corrected]
    Z Gluzman-Poltorak
    Department of Biology, Technion, Israel Institute of Technology, Haifa 32000, Israel
    J Biol Chem 275:18040-5. 2000
    ..Nevertheless, it is possible that VEGF-induced np-2-mediated signaling will take place only in the presence of other VEGF receptors such as VEGF receptor-1 or VEGF receptor-2...
  50. ncbi In oesophageal squamous cell carcinoma vascular endothelial growth factor is associated with p53 mutation, advanced stage and poor prognosis
    S Uchida
    Department of Surgery and Surgical Basic Science, Graduate School of Medicine, Kyoto University, Japan
    Br J Cancer 77:1704-9. 1998
    ..0077). We have assumed that VEGF contributes to aggressive characteristics in oesophageal carcinomas and that VEGF expression might be affected by p53 status...
  51. ncbi Src mediates stimulation by vascular endothelial growth factor of the phosphorylation of focal adhesion kinase at tyrosine 861, and migration and anti-apoptosis in endothelial cells
    R Abu-Ghazaleh
    Department of Medicine, University College London, 5 University Street, London WC1E 6JJ, UK
    Biochem J 360:255-64. 2001
    ....
  52. ncbi Cyclooxygenase 2- and prostaglandin E(2) receptor EP(2)-dependent angiogenesis in Apc(Delta716) mouse intestinal polyps
    Hiroshi Seno
    Department of Pharmacology, Kyoto University Graduate School of Medicine, Kyoto 606 8501, Japan
    Cancer Res 62:506-11. 2002
    ....
  53. ncbi Matrix metalloproteinases cleave connective tissue growth factor and reactivate angiogenic activity of vascular endothelial growth factor 165
    Gakuji Hashimoto
    Department of Pathology, School of Medicine, Keio University, 35 Shinanomachi, Shinjuku ku, Tokyo, Japan
    J Biol Chem 277:36288-95. 2002
    ..MMPs may play a novel role through CTGF degradation in VEGF-induced angiogenesis during embryonic development, tissue maintenance, and/or pathological processes of various diseases...
  54. ncbi Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy
    Harold F Dvorak
    Department of Pathology, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
    J Clin Oncol 20:4368-80. 2002
    ..It may also become an important target for cancer therapy...
  55. ncbi Expression of vascular endothelial growth factor during embryonic angiogenesis and endothelial cell differentiation
    G Breier
    Max Planck Institut fur Psychiatrie, Martinsried, FRG
    Development 114:521-32. 1992
    ..g. in choroid plexus and in kidney glomeruli. The data are consistent with a role of VEGF as a multifunctional regulator of endothelial cell growth and differentiation...
  56. ncbi Constitutive production and thrombin-induced release of vascular endothelial growth factor by human megakaryocytes and platelets
    R Mohle
    Developmental Hematopoiesis Laboratory, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Proc Natl Acad Sci U S A 94:663-8. 1997
    ..Within the bone marrow microenvironment, VEGF secreted by megakaryocytes may contribute to the proliferation of endothelial cells. VEGF delivered to sites of vascular injury by activated platelets may initiate angiogenesis...
  57. ncbi VEGF is required for growth and survival in neonatal mice
    H P Gerber
    Departments of Cardiovascular Research and Pathology, Genentech, Inc, South San Francisco, CA 94080, USA
    Development 126:1149-59. 1999
    ..Thus, VEGF is essential for growth and survival in early postnatal life. However, in the fully developed animal, VEGF is likely to be involved primarily in active angiogenesis processes such as corpus luteum development...
  58. ncbi Angiogenesis promoted by vascular endothelial growth factor: regulation through alpha1beta1 and alpha2beta1 integrins
    D R Senger
    Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA 02215, USA
    Proc Natl Acad Sci U S A 94:13612-7. 1997
    ....
  59. ncbi Host cyclooxygenase-2 modulates carcinoma growth
    C S Williams
    Department of Medicine, The Vanderbilt Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee 37232 2279, USA
    J Clin Invest 105:1589-94. 2000
    ..Additionally, treatment of wild-type mouse fibroblasts with a selective COX-2 inhibitor reduced VEGF production by 92%...
  60. ncbi Human vascular permeability factor. Isolation from U937 cells
    D T Connolly
    Department of Cell Culture, Monsanto Company, St Louis, Missouri 63167
    J Biol Chem 264:20017-24. 1989
    ..The N-terminal amino acid sequence of hVPF was similar to, but not identical with, the N-terminal sequence of guinea pig vascular permeability factor...
  61. ncbi Prognostic significance of vascular endothelial growth factor expression in human ovarian carcinoma
    G H Shen
    Department of Molecular Pathology, Institute of Gerontology, Nippon Medical School, Kawasaki, Japan
    Br J Cancer 83:196-203. 2000
    ....
  62. ncbi Vascular permeability factor, an endothelial cell mitogen related to PDGF
    P J Keck
    Department of Cell Culture and Biochemistry, Monsanto Company, St Louis, MO 63167
    Science 246:1309-12. 1989
    ..Clusters of basic amino acids in the COOH-terminal halves of human VPF and PDGF-B are also prevalent. Thus, VPF appears to be related to the PDGF/v-sis family of proteins...
  63. ncbi Correlation of increased vascular endothelial growth factor with neovascularization and permeability in ischemic central vein occlusion
    Shelley R Boyd
    Moorfields Eye Hospital, City Road, London EC1V 2PD, England
    Arch Ophthalmol 120:1644-50. 2002
    ....
  64. ncbi Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function
    D I Gabrilovich
    Department of Medicine and The Vanderbilt Cancer Center, Vanderbilt University School of Medicine, Nashville, Tennessee 37232 6838, USA
    Clin Cancer Res 5:2963-70. 1999
    ..This effect was associated with the induction of significant anti-p53 CTL responses only in this group of mice. These data suggest that inhibition of VEGF may be a valuable adjuvant in the immunotherapy of cancer...
  65. ncbi Paracrine and autocrine functions of neuronal vascular endothelial growth factor (VEGF) in the central nervous system
    Omolara O Ogunshola
    Department of Pathology, Yale University School of Medicine, New Haven, Connecticut 06510, USA
    J Biol Chem 277:11410-5. 2002
    ..Thus, our in vitro data support a role for neuronal VEGF in both paracrine and autocrine signaling in the maintenance of neurons and endothelia in the central nervous system...
  66. ncbi Adenoviral VEGF-C overexpression induces blood vessel enlargement, tortuosity, and leakiness but no sprouting angiogenesis in the skin or mucous membranes
    Anne Saaristo
    Molecular/Cancer Biology Laboratory and Ludwig Institute for Cancer Research, Biomedicum, University of Helsinki and Helsinki University Central Hospital, 00014 Helsinki, Finland
    FASEB J 16:1041-9. 2002
    b>Vascular endothelial growth factors (VEGFs) and their receptors (VEGFRs) are important regulators of blood and lymphatic vessel growth and vascular permeability...
  67. ncbi Extracellular matrix-bound vascular endothelial growth factor promotes endothelial cell adhesion, migration, and survival through integrin ligation
    Helen Hutchings
    GDR CNRS 1927-Angiogenese and UMR CNRS 5089, Institut de Pharmacologie et Biologie Structurale, Toulouse, France
    FASEB J 17:1520-2. 2003
    ..We have thus determined a new VEGF receptor-independent role for immobilized VEGF in supporting cell adhesion and survival through interactions with integrins...
  68. ncbi Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor
    S Soker
    Department of Surgery, Children s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
    Cell 92:735-45. 1998
    ..We propose that neuropilin-1 is a novel VEGF receptor that modulates VEGF binding to KDR and subsequent bioactivity and therefore may regulate VEGF-induced angiogenesis...
  69. ncbi Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha
    R Ravi
    Johns Hopkins Oncology Center, Departments of Pediatrics and Medicine, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21287 USA
    Genes Dev 14:34-44. 2000
    ..These results indicate that amplification of normal HIF-1-dependent responses to hypoxia via loss of p53 function contributes to the angiogenic switch during tumorigenesis...
  70. ncbi Simultaneous elevation in the serum concentrations of the angiogenic growth factors VEGF and bFGF is an independent predictor of poor prognosis in non-Hodgkin lymphoma: a single-institution study of 200 patients
    P Salven
    Department of Cell Biology, New York University School of Medicine, New York, NY 10016, USA
    Blood 96:3712-8. 2000
    ..The authors conclude that the combination of S-VEGF and S-bFGF is a powerful prognostic variable in NHL. (Blood. 2000;96:3712-3718)..
  71. ncbi Hypoxia and vascular endothelial growth factor expression in human squamous cell carcinomas using pimonidazole as a hypoxia marker
    J A Raleigh
    Department of Radiation Oncology, University of North Carolina School of Medicine, Chapel Hill 27599, USA
    Cancer Res 58:3765-8. 1998
    ..A quantitative immunohistochemical comparison of hypoxia and VEGF protein expression revealed no correlation between the two factors...
  72. ncbi Enhancement of pleural dissemination and lymph node metastasis of intrathoracic lung cancer cells by vascular endothelial growth factors (VEGFs)
    Haruhiko Ishii
    Department of Surgery, Yokohama City University School of Medicine, 3 9 Fukuura, Kanazawa Ku, Yokohama, Kanagawa 236 0004, Japan
    Lung Cancer 45:325-37. 2004
    The expression of vascular endothelial growth factors (VEGFs) in tumors including lung cancer is considered to be associated with tumor development via capillary and lymph vessel neogenesis...
  73. ncbi SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo
    Anne Marie O'Farrell
    Preclinical Research and Exploratory Development, SUGEN, South San Francisco, CA 94080, USA
    Blood 101:3597-605. 2003
    ..These results suggest that further exploration of SU11248 activity in AML patients is warranted...
  74. ncbi Snake venom vascular endothelial growth factors (VEGFs) exhibit potent activity through their specific recognition of KDR (VEGF receptor 2)
    Yasuo Yamazaki
    Department of Biochemistry, Meiji Pharmaceutical University, 2 522 1, Noshio, Kiyose, Tokyo 204 8588, Japan
    J Biol Chem 278:51985-8. 2003
    ..Our data clearly indicate that snake venom VEGFs act through the specific activation of KDR and show potent effects. Snake venom VEGFs are a highly specific ligand to KDR and form a new group of the VEGF family...
  75. ncbi In vitro regulation of vascular endothelial growth factor by estrogens and antiestrogens in estrogen-receptor positive breast cancer
    Hiroyuki Takei
    Northwestern University Medical School, Robert H Lurie Comprehensive Cancer Center, USA
    Breast Cancer 9:39-42. 2002
    ..In this study we investigated the in vitro effects of antiestrogens at different concentrations on vascular endothelial growth factor (VEGF) production in estrogen receptor (ER)-positive breast cancer cells...
  76. ncbi Enhanced expressions of matrix metalloproteinase (MMP)-2 and -9 and vascular endothelial growth factors (VEGF) and increased microvascular density in the endometrial hyperplasia of women with anovulatory dysfunctional uterine bleeding
    Xinmei Zhang
    Women s Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310006, People s Republic of China
    Fertil Steril 93:2362-7. 2010
    To evaluate the roles of endometrial matrix metalloproteinase (MMP)-2 and -9, vascular endothelial growth factors (VEGF), and microvascular density (MVD) in the occurrence of anovulatory dysfunctional uterine bleeding (DUB).
  77. ncbi Ionizing radiation modulates vascular endothelial growth factor (VEGF) expression through multiple mitogen activated protein kinase dependent pathways
    J S Park
    Department of Radiation Oncology, Medical College of Virginia, Virginia Commonwealth University, Richmond, Virginia, VA 23298, USA
    Oncogene 20:3266-80. 2001
    ..Enhanced VEGF expression in RT2 cells may be mediated via MAPK and JNK pathway signaling which converges upon the AP-1 transcription factor complex...
  78. ncbi Vascular endothelial growth factor A (VEGF-A) mRNA expression levels decrease after menopause in normal breast tissue but not in breast cancer lesions
    R R Greb
    Department of Obstetrics and Gynecology, University Hospital, , Germany
    Br J Cancer 81:225-31. 1999
    ..Endogenous and therapeutically used hormonal steroids might, therefore, cause clinically relevant changes of the angiogenic phenotype of the human breast...
  79. ncbi Dual mechanism of vascular endothelial growth factor upregulation by hypoxia in human hepatocellular carcinoma
    Z von Marschall
    Department of Hepatology and Gastroenterology, Charite, Campus Virchow Klinikum, Humboldt University, Augustenburger Platz 1, 13353 Berlin, Germany
    Gut 48:87-96. 2001
    ..In the current study we analysed expression of VEGF and its receptors in human hepatocellular carcinoma (HCC) and investigated the molecular mechanisms of VEGF regulation by hypoxia...
  80. ncbi Src deficiency or blockade of Src activity in mice provides cerebral protection following stroke
    R Paul
    Departments of Immunology and Vascular Biology, The Scripps Research Institute, La Jolla, California, USA
    Nat Med 7:222-7. 2001
    ..Thus, Src represents a key intermediate and novel therapeutic target in the pathophysiology of cerebral ischemia where it appears to regulate neuronal damage by influencing VEGF-mediated VP...
  81. ncbi Expression of cyclo-oxygenase 1 and 2, prostaglandin E synthase and transforming growth factor beta1, and their relationship with vascular endothelial growth factors A and C, in primary adenocarcinoma of the small intestine
    B H A Von Rahden
    Department of Surgery, Technical University of Munich, Munich, Germany
    Br J Surg 93:1424-32. 2006
    ..Promotion of tumour growth by transforming growth factor (TGF) beta may be mediated through the prostaglandin pathway...
  82. ncbi VEGF inhibitors and prostate cancer therapy
    Jeanny B Aragon-Ching
    Department of Medicine, Division of Hematology and Oncology, George Washington University Medical Center, Washington, DC 20037, USA
    Curr Mol Pharmacol 2:161-8. 2009
    ..Results of key clinical trials associated with the use of these agents and future directions are discussed herein...
  83. ncbi Selective blockade of vascular endothelial growth factor receptor 2 with an antibody against tumor-derived vascular endothelial growth factor controls the growth of human pancreatic adenocarcinoma xenografts
    Shane E Holloway
    Department of Surgery, Division of Surgical Oncology, Hamon Center for Therapeutic Oncology Research, University of Texas Southwestern Medical Center, 6000 Harry Hines Boulevard, Dallas, Texas 75390-8593, USA
    Ann Surg Oncol 13:1145-55. 2006
    ..CONCLUSIONS: Blockade of VEGF receptor 2 activation by tumor-derived VEGF decreases tumor vessel function and growth of some human pancreatic adenocarcinoma cell lines in mice...
  84. ncbi Recruitment of stem and progenitor cells from the bone marrow niche requires MMP-9 mediated release of kit-ligand
    Beate Heissig
    Division of Hematology Oncology, Cornell University Medical College, New York, NY 10021, USA
    Cell 109:625-37. 2002
    ..Release of sKitL by MMP-9 enables BM repopulating cells to translocate to a permissive vascular niche favoring differentiation and reconstitution of the stem/progenitor cell pool...
  85. ncbi Correlation between vascular endothelial growth factor, angiogenesis, and tumor-associated macrophages in invasive ductal breast carcinoma
    Toni Valković
    Department of Pathology, Medical Faculty, University of Rijeka, B Branchetta 20, 51000 Rijeka, Croatia
    Virchows Arch 440:583-8. 2002
    ..The expression of this angiogenic molecule, and MVD and TAM level, can provide additional prognostic significance and help in the identification of patients who need postoperative adjuvant therapy...
  86. ncbi Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor
    R L Kendall
    Department of Biochemistry, Merck Research Laboratories, Rahway, NJ 07065
    Proc Natl Acad Sci U S A 90:10705-9. 1993
    ....
  87. ncbi Novel role of gp91(phox)-containing NAD(P)H oxidase in vascular endothelial growth factor-induced signaling and angiogenesis
    Masuko Ushio-Fukai
    Division of Cardiology, Department of Medicine, Emory University School of Medicine, Atlanta, GA 30322, USA
    Circ Res 91:1160-7. 2002
    ....
  88. ncbi Differential expression of the two VEGF receptors flt and KDR in placenta and vascular endothelial cells
    B Barleon
    Institute of Molecular Cell Biology, University of Freiburg, Germany
    J Cell Biochem 54:56-66. 1994
    ....
  89. ncbi Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1
    Aernout Luttun
    Center for Transgene Technology and Gene Therapy, Flanders Interuniversity Institute for Biotechnology, University of Leuven, Leuven, Belgium
    Nat Med 8:831-40. 2002
    ..Thus, PlGF and Flt1 constitute potential candidates for therapeutic modulation of angiogenesis and inflammation...
  90. ncbi The role of VEGF in normal and neoplastic hematopoiesis
    Hans Peter Gerber
    Department of Molecular Oncology, Genentech Inc, 1 DNA Way, South San Francisco, CA 94080, USA
    J Mol Med (Berl) 81:20-31. 2003
    ....
  91. ncbi VEGF-induced paracellular permeability in cultured endothelial cells involves urokinase and its receptor
    M Ali Behzadian
    Vascular Biology Center, Department of Pharmacology and Toxicology, Medical College of Georgia, 1120 15th Street, Augusta, Georgia 30912, USA
    FASEB J 17:752-4. 2003
    ..In conclusion, VEGF induces a sustained paracellular permeability in capillary endothelial cells that is mediated by activation of the uPA/uPAR system...
  92. ncbi Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR
    J E Park
    Genentech, Inc, South San Francisco, California 94080
    J Biol Chem 269:25646-54. 1994
    ..Purified PIGF isoforms had little or no direct mitogenic or permeability-enhancing activity. However, they were able to significantly potentiate the action of low concentrations of VEGF in vitro and, more strikingly, in vivo...
  93. ncbi Conditional switching of VEGF provides new insights into adult neovascularization and pro-angiogenic therapy
    Yuval Dor
    Department of Molecular Biology, Hebrew University Hadassah Medical School, MRI MRS Laboratory, HBRC, Hadassah University Hospital, Jerusalem 91120, Israel
    EMBO J 21:1939-47. 2002
    ..This novel genetic system thus highlights remaining problems in the implementation of pro-angiogenic therapy...
  94. ncbi Vascular endothelial growth factor (VEGF) and its receptors
    G Neufeld
    Department of Biology, Technion, Israel Institute of Technology, Technion City, Haifa 32000, Israel
    FASEB J 13:9-22. 1999
    ....
  95. ncbi Role of vascular endothelial growth factor in regulation of physiological angiogenesis
    N Ferrara
    Department of Molecular Oncology, Genentech, Inc, South San Francisco, CA 94080, USA
    Am J Physiol Cell Physiol 280:C1358-66. 2001
    ..Substantial evidence also implicates VEGF as an angiogenic mediator in tumors and intraocular neovascular syndromes, and numerous clinical trials are presently testing the hypothesis that inhibition of VEGF may have therapeutic value...
  96. ncbi Muscle adaptation to altitude: tissue capillarity and capacity for aerobic metabolism
    O Mathieu-Costello
    Department of Medicine, University of California, San Diego, La Jolla, CA 92093 0623, USA
    High Alt Med Biol 2:413-25. 2001
    ..In this mini review, we summarize these data and current knowledge on muscle capillary to fiber structural relationships and their implications for muscle aerobic function at altitude...
  97. ncbi Lymphatic versus blood vascular endothelial growth factors and receptors in humans
    T A Partanen
    Molecular/Cancer Biology Laboratory and Department of Pathology, Haartman Institute and Biomedicum Helsinki University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland
    Microsc Res Tech 55:108-21. 2001
    ..These are vascular endothelial growth factors (VEGFs), angiopoietins, and ephrins...
  98. ncbi Regulation of angiogenesis and endothelial cell function by connective tissue growth factor (CTGF) and cysteine-rich 61 (CYR61)
    David R Brigstock
    Department of Surgery, The Ohio State University, Columbus, Ohio, USA
    Angiogenesis 5:153-65. 2002
    ....
  99. ncbi Transcription factor Egr-1 supports FGF-dependent angiogenesis during neovascularization and tumor growth
    Roger G Fahmy
    Centre for Vascular Research, University of New South Wales, Sydney NSW 2052, Australia
    Nat Med 9:1026-32. 2003
    ..Egr-1 DNAzymes also repressed neovascularization of rat cornea. Thus, microvascular endothelial cell growth, neovascularization, tumor angiogenesis and tumor growth are processes that are critically dependent on Egr-1...
  100. ncbi Anti-cancer effect of genistein in oral squamous cell carcinoma with respect to angiogenesis and in vitro invasion
    Hoon Myoung
    Department of Oral and Maxillofacial Surgery, College of Dentistry and Dental Research Institute, Seoul National University, 28-2, Yun-Gun dong, Chong-No gu, Seoul, Korea
    Cancer Sci 94:215-20. 2003
    ..As a result, further research is recommended to confirm that genistein may be employed as an adjunct treatment modality for OSCC...
  101. ncbi Combination therapy with paclitaxel and thalidomide inhibits angiogenesis and growth of human colon cancer xenograft in mice
    Toshiyuki Fujii
    Second Department of Surgery, Shimane Medical University, Enya cho 89 1, Izumo 693 8501, Shimane, Japan
    Anticancer Res 23:2405-11. 2003
    ..Paclitaxel is a potent anti-tumor agent but has dose-limiting side-effects, whereas thalidomide is an orally active anti-angiogenic drug but less than sufficient to exert anti-tumor effect as a single agent...

Research Grants83

  1. Role of a9b1 Integrin in lymphangiogenesis
    Nicholas Vlahakis; Fiscal Year: 2007
    ..This KO8 program will support investigations into the role of alpha9-beta1 integrin and vascular endothelial growth factors (VEGF) C and D in pulmonary lymphatic development and function...
  2. VEGFs in Artery-Vein Imbalance in AIDS-Kaposi Sarcoma
    Parkash Gill; Fiscal Year: 2009
    ..This work is anticipated to enhance our understanding of KS pathogenesis, provide opportunities for novel therapies for KS, and contribute to the understanding of vascular biology. ..
  3. VEGFs in Artery-Vein Imbalance in AIDS-Kaposi Sarcoma
    Parkash Gill; Fiscal Year: 2007
    ..This work is anticipated to enhance our understanding of KS pathogenesis, provide opportunities for novel therapies for KS, and contribute to the understanding of vascular biology. ..
  4. Vascular endothelial growth factor induced lung edema
    Robert Kaner; Fiscal Year: 2004
    ..Bronchoalveolar lavage and plasma levels of VEGF will be measured in patients with acute lung injury to develop the hypothesis that overexpression of VEGF in lung may be one mechanism favoring increased permeability. ..
  5. A Novel Model to Study Retinopathy of Prematurity
    David Moscatelli; Fiscal Year: 2003
    ..Our model will provide a useful tool to directly examine the roles of various factors in retinal vascular diseases in a setting that maintains normal tissue architecture. ..
  6. Augmentation of Lymphangiogenesis by Increased Fluid Channeling in Mouse Skin
    Jeremy Goldman; Fiscal Year: 2007
    b>Vascular endothelial growth factors (VEGF)-C and -D have been shown to be necessary for lymphatic proliferation and migration during lymphangiogenesis by binding VEGFR-3 on lymphatic endothelial cells...
  7. VEGFs in tumor lymphatic metastasis
    HAROLD FISHER DVORAK; Fiscal Year: 2010
    ..This application is focused on understanding the mechanisms that these factors use to induce lymphangiogenesis and metastasis in melanoma, as well as how these mechanisms impact emerging cancer therapies. ..
  8. THE MAJOR ANGIOGENIC FACTORS IN PLACENTAL ANGIOGENESIS
    Lawrence Reynolds; Fiscal Year: 2004
    ..Recent studies, including those in gene-knockout mice, indicate that vascular endothelial growth factors (VEGF), fibroblast growth factors (FGF), and angiopoietins (ANG) play major roles in the ..
  9. Integrins and bone matrix in prostate cancer
    Tatiana Byzova; Fiscal Year: 2006
    ..abstract_text> ..
  10. Integrins and bone matrix in prostate cancer
    Tatiana Byzova; Fiscal Year: 2003
    ....
  11. Genetic Control of Cranial Neural Crest Migration
    Hung Hsiang Yu; Fiscal Year: 2005
    ..of neuropilin 2 (Npn-2), a binding receptor for class 3 secreted semaphorin 3C and 3F and vascular endothelial growth factors in vertebrates...
  12. Angiogenesis in Myocardial Ischemia
    Michael Simons; Fiscal Year: 2007
    ..abstract_text> ..
  13. GENETICS OF VEGF MEDIATED ANGIOGENESIS IN MOUSE SKIN
    Bruce Herron; Fiscal Year: 2009
    ..The Vascular Endothelial Growth Factors (VEGF) are a family of secreted glycoproteins that control angiogenesis...
  14. GENETICS OF VEGF MEDIATED ANGIOGENESIS IN MOUSE SKIN
    Bruce J Herron; Fiscal Year: 2010
    ..The Vascular Endothelial Growth Factors (VEGF) are a family of secreted glycoproteins that control angiogenesis...
  15. Angiogenesis:Novel Basic Science Insight & Human Therapy
    Napoleone Ferrara; Fiscal Year: 2004
    ..abstract_text> ..
  16. Regulation of Coronary Vessel Assembly and Growth
    Robert Tomanek; Fiscal Year: 2007
    ..Since cardiac development depends on timely and adequate vascularization, an understanding of coronary vasculogenesis and angiogenesis will provide an important foundation for our understanding of cardiac defects. ..
  17. ANGIOGENIC THERAPY FOR INFARCTED AND ISCHEMIC HEART
    Robert Tomanek; Fiscal Year: 2003
    ..Such interventions have a number of advantages over more invasive interventions, e.g., the delivery of oxogenous growth factors or gene therapy. ..
  18. Nitric Oxide in Tumor Angiogenesis, Microcirculation and Radiation Therapy
    Dai Fukumura; Fiscal Year: 2010
    ..This project will advance the basic understanding of NO-mediated vessel maturation and help develop novel strategies to improve the delivery of drugs and oxygen to tumors. ..
  19. Skin Manifestations of Tuberous Sclerosis
    Jack Arbiser; Fiscal Year: 2009
    ..Specific Aim 3. To determine whether dysregulation of p16ink4a and PTCH (patched) acts as a modifier of theTS phenotype in transgenic mice expressing dominant negative tuberin. ..
  20. NO in Tumor Angiogenesis,Microcirculation & Rad.Therapy
    Dai Fukumura; Fiscal Year: 2006
    ..e. normalization of tumor vessels) to overcome some of the physiological barriers to the delivery of therapeutic agents to solid tumors and introduce a new paradigm to study cell-cell interaction in vivo. ..
  21. Role of BMDCs in Solid Tumor Growth and Relapse
    Rakesh Jain; Fiscal Year: 2009
    ..Furthermore, our results will offer strategies for the inhibition of tumor relapse after radiotherapy by targeting molecular pathways that are critical for both angiogenesis and myeloid BMDC recruitment. ..
  22. Effects of the Angiopoietins on Tie 2 Downregulation
    Christopher Kontos; Fiscal Year: 2005
    ..abstract_text> ..
  23. Conference on Angiogenesis in Cancer and Other Diseases
    Rakesh Jain; Fiscal Year: 2002
    ..The meeting's synthesis of available information will be particularly thought-provoking for students and post- doctoral fellows. ..
  24. MOLECULAR REGULATION AND ROLE OF PLACENTA GROWTH FACTOR
    Donald Torry; Fiscal Year: 2002
    ..abstract_text> ..